chlorpromazine has been researched along with ciprofloxacin in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (35.48) | 29.6817 |
| 2010's | 16 (51.61) | 24.3611 |
| 2020's | 4 (12.90) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Keserü, GM | 1 |
| Caron, G; Ermondi, G | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Brandini, D; Fravolini, A; Kaatz, GW; Rossolini, GM; Sabatini, S | 1 |
| Bailey, AM; Paulsen, IT; Piddock, LJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Gozalbes, R; Pineda-Lucena, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Sen, S; Sinha, N | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Bucar, F; Gröblacher, B; Kunert, O | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Artym, J; Jeleń, M; Kocięba, M; Morak-Młodawska, B; Pluta, K; Zaczyńska, E; Zimecki, M | 1 |
| Barreca, ML; Cannalire, R; Cecchetti, V; Couto, I; Felicetti, T; Machado, D; Manfroni, G; Massari, S; Sabatini, S; Santos Costa, S; Tabarrini, O; Viveiros, M | 1 |
| Alves Borges Leal, AL; Araújo de Oliveira Alcântara, F; Barreto, HM; de Siqueira-Júnior, JP; Faillace, MS; Ferreira, JHL; Peláez, WJ; Sampaio Nogueira, CE | 1 |
| Aboshanab, KM; Aboulwafa, MM; Ahmed, MT; Anwer, BE; Mohammed, MA | 1 |
| Aron, Z; Attwood, MLG; Barber, R; Grimsey, E; MacGowan, AP; Noel, AR; Opperman, TJ; Piddock, LJV; Ricci, V; Stone, J | 1 |
| Araújo, IM; Barbosa-Filho, JM; Bezerra da Cunha, FA; Bezerra, AH; Datiane de Morais Oliveira-Tintino, C; de Sousa Silveira, Z; de Souza-Ferrari, J; Freitas, TS; Macêdo, NS; Marinho, ES; Marinho, MM; Melo Coutinho, HD; Muniz, DF; Nunes da Rocha, M; Ribeiro de Sousa, G; Rocha, JE; Rodrigues Dos Santos Barbosa, C; Silva Dos Santos, H | 1 |
2 review(s) available for chlorpromazine and ciprofloxacin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Azaphenothiazines - promising phenothiazine derivatives. An insight into nomenclature, synthesis, structure elucidation and biological properties.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Antiprotozoal Agents; Antipsychotic Agents; Bacteria; Fungi; Humans; Leishmania; Molecular Structure; Neoplasms; Phenothiazines | 2017 |
29 other study(ies) available for chlorpromazine and ciprofloxacin
| Article | Year |
|---|---|
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
Topics: 1-Octanol; Alkanes; Hydrogen-Ion Concentration; Least-Squares Analysis; Mathematics; Models, Chemical; Models, Molecular; Solvents; Water | 2005 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
From phenothiazine to 3-phenyl-1,4-benzothiazine derivatives as inhibitors of the Staphylococcus aureus NorA multidrug efflux pump.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Microbial Sensitivity Tests; Multidrug Resistance-Associated Proteins; Phenothiazines; Staphylococcus aureus; Thiazines | 2008 |
RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
Topics: Anti-Bacterial Agents; Antipsychotic Agents; Bacterial Proteins; Base Sequence; Chlorpromazine; DNA Primers; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Synergism; Ethidium; Gene Expression; Genes, Bacterial; Humans; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Mutation; Oligonucleotide Array Sequence Analysis; Phenothiazines; Salmonella typhimurium; Trans-Activators | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Compounds of Alpinia katsumadai as potential efflux inhibitors in Mycobacterium smegmatis.
Topics: Alpinia; Antibiotics, Antitubercular; Antitubercular Agents; Diarylheptanoids; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium smegmatis; Plant Extracts; Seeds | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
Topics: Anti-Bacterial Agents; Drug Design; Genistein; Mycobacterium avium; Quinolones | 2017 |
Inhibition of the NorA efflux pump of S. aureus by (Z)-5-(4-Fluorobenzylidene)-Imidazolidines.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Dose-Response Relationship, Drug; Imidazolidines; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Multidrug Resistance-Associated Proteins; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship | 2021 |
Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Chlorpromazine; Ciprofloxacin; Cross Infection; Diclofenac; Disk Diffusion Antimicrobial Tests; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Egypt; Fluoroquinolones; Humans; Levofloxacin; Propranolol | 2020 |
Exposure of Escherichia coli to antibiotic-efflux pump inhibitor combinations in a pharmacokinetic model: impact on bacterial clearance and drug resistance.
Topics: Anti-Bacterial Agents; Chlorpromazine; Ciprofloxacin; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Escherichia coli; Microbial Sensitivity Tests | 2023 |
Evaluation of the antibacterial and inhibitory activity of the MepA efflux pump of Staphylococcus aureus by riparins I, II, III, and IV.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Benzamides; Chlorpromazine; Ciprofloxacin; Ethidium; Microbial Sensitivity Tests; Molecular Docking Simulation; Staphylococcus aureus | 2023 |